These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 1552042

  • 1. Lack of efficacy of lithium augmentation in obsessive-compulsive disorder: the perspective of different regional effects of lithium on serotonin release in the central nervous system.
    Blier P, de Montigny C.
    J Clin Psychopharmacol; 1992 Feb; 12(1):65-6. PubMed ID: 1552042
    [No Abstract] [Full Text] [Related]

  • 2. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR.
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [Abstract] [Full Text] [Related]

  • 3. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.
    Rasmussen SA.
    Am J Psychiatry; 1984 Oct; 141(10):1283-5. PubMed ID: 6435460
    [Abstract] [Full Text] [Related]

  • 4. Obsessive-compulsive disorder and serotonin: is there a connection?
    Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL.
    Biol Psychiatry; 1985 Nov; 20(11):1174-88. PubMed ID: 2413912
    [Abstract] [Full Text] [Related]

  • 5. Lithium for obsessive-compulsive disorder?
    Jefferson JW, Greist JH, Baudhuin M, Ackerman D.
    Psychosomatics; 1984 Jun; 25(6):493. PubMed ID: 6739703
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of obsessive-compulsive disorder with lithium carbonate.
    Stern TA, Jenike MA.
    Psychosomatics; 1983 Jul; 24(7):671-3. PubMed ID: 6414009
    [No Abstract] [Full Text] [Related]

  • 7. Lithium as an adjunct treatment in obsessive-compulsive disorder.
    Eisenberg J, Asnis G.
    Am J Psychiatry; 1985 May; 142(5):663. PubMed ID: 3985216
    [No Abstract] [Full Text] [Related]

  • 8. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR.
    Am J Psychiatry; 1990 May; 147(5):652-4. PubMed ID: 1970224
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD.
    Feenstra MGP, Klompmakers A, Figee M, Fluitman S, Vulink N, Westenberg HGM, Denys D.
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):310-319. PubMed ID: 26712326
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A review of the role of serotonin system genes in obsessive-compulsive disorder.
    Sinopoli VM, Burton CL, Kronenberg S, Arnold PD.
    Neurosci Biobehav Rev; 2017 Sep; 80():372-381. PubMed ID: 28576508
    [Abstract] [Full Text] [Related]

  • 20. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS.
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.